{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-090853","form_type":"8-K/A","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.298247+00:00","generated_at":"2026-06-17T06:27:59.397376+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CalciMedica files audited FY2022 financials post-reverse merger; net loss $14.5M","bullets":["Net loss of $14.5M in 2022, accumulated deficit $118.4M as of Dec 31, 2022.","Cash and cash equivalents $1.3M at year-end 2022; merger and private placement raised ~$34.2M in March 2023.","Reverse merger closed March 20, 2023; Graybug Vision renamed CalciMedica, surviving as public entity.","Former CalciMedica stockholders own ~72% of combined company on fully diluted basis.","Going concern opinion included; management expects new funds to support operations beyond 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-090853","json":"https://secwatch.observer/filing/0001193125-23-090853.json","markdown":"https://secwatch.observer/filing/0001193125-23-090853.md","text":"https://secwatch.observer/filing/0001193125-23-090853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523090853/0001193125-23-090853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312523090853/d471673d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:27:59.397376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}